期刊文献+

HIV-1中和抗体检测方法的建立 被引量:1

Development of A Method for Determination of HIV-1 Neutralizing Antibody
在线阅读 下载PDF
导出
摘要 目的以荧光素酶作为报告基因,表达假病毒,建立快速、有效的HIV-1中和抗体检测方法。方法将HIV-1中国流行株B/C重组亚型和C亚型Envelope基因的真核表达质粒分别与带有荧光素酶报告基因的pNL4-3.Luc.R-E质粒共转染293T细胞,培养48h后收获含有假病毒的上清液,感染表达CD4受体和一个辅助受体CCR5的HOS细胞,培养72h后,裂解细胞,检测荧光素酶含量。结果HIV-1的B/C重组亚型和C亚型Envelope基因真核表达质粒分别与pNL4-3.Luc.R-E质粒共转染的293T细胞,均有HIV-1结构蛋白Gagpol和Env的表达,相对分子质量分别为55000和160000,用产生的假病毒感染HOS-CD4-CCR5/CXCR4细胞后,产生的荧光素酶含量明显高于对照组。结论已建立了瞬时转染检测HIV-1中和抗体的方法,为今后抗体样本及病毒样本的检测提供了参考。 Objective To express pseudovirus using luciferase as report gene and develop a rapid and effective method for determination of HIV-1 neutralizing antibody. Methods Transfect 293T cells by pNL4-3.Luc.R-E together with eukaryotic expression plasmids pcDNA3. 1 EnvB/C and YR1012EnvC respectively and culture for 48 h. The supernatant containing pseudovirus was harvested to infect HOS cells expressing receptor CD4 and accessory receptor CCRS. The infected cells were cultured for 72 h, then lysed and determined for lueiferase content. Results HIV-1 structural proteins Gagpol and Env, with relative molecular mass of 55 000 and 160 000 respectively, were expressed in 293T cells co-transfected with pcDNA3. 1 EnvB/C and pNL4-3. Luc. R-E as well as those with VR1012EnvC and pNL4-3. Luc. R-E. The luciferase content in HOS-CD4-CCR5/CXCR4 cells infected with the harvested pseudovirus was significantly higher than that in control. Conclusion A method for determination of HIV-1 neutralizing antibody by transient transfection was developed, which provided a basis for the determination of antibody and virus specimens.
出处 《中国生物制品学杂志》 CAS CSCD 2008年第9期810-812,共3页 Chinese Journal of Biologicals
基金 国家自然科学基金(30371317)
关键词 人免疫缺陷病毒1型 中和抗体 荧光素酶 假病毒 Human immunodeficiency virus type 1 Neutralizing antibody Luciferase Pseudovirus
  • 相关文献

参考文献4

二级参考文献22

  • 1Sattentau QJ,Moulard M,Bnvet B,et al.Antibody neutralization of HIV-1 and the potential for vaccine design.Immunol Lett,1999,66(1-3): 143-149.?A
  • 2Thomas Lehner.The role of CCR5 chemokine ligands and antibodies to CCR5 corecepotors in poreventing HIV infection.Trends in Immunology,2002,23(7) :347-351.?A
  • 3Ruprecht RM,Ferrantelli F,Kitabwalla M,et al.Antibody protection: passive immunization of neonates against oral AIDS virus challenge.Vaccine,2003,21(24):3370-3373.?A
  • 4Ferrantelli F,Ruprecht RM.Neutralizing ahtibodies against HIV-back in the major leagues? Current Opinion in Immunology,2002,14:495-502.?A
  • 5Saphire EO,Parren PW,Pantophlet R,et al.Crystal structure of a neutralizing human IgG against HIV-1 :A template for vaccine design.Science,2001,293(10): 1155-1159.?A
  • 6Ferrantelli F,Rasmussen RA,Hofmann-Lehmann R,et al.Do not underestimate the power of antibodies-lessons from adoptive transfer of antibodies against HIV.Vaccine,2002,20(Suppl 4A)6: 1-6.?A
  • 7Chakrabarti BK,Kong W,Wu B,et al.Modifications of the human immunodefiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.J Virol,2002,76(11) :5357-5368.?A
  • 8Barnett SW,Lu S,Srivastava I,et al.The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.J Virol,2001,75 (12): 5526-5540.?A
  • 9Malenbaum SE,Yang D,Cheng-Mayer C.Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp 120 in humans and macaques.J Virol,2001,75(19) :9287-9296.?A
  • 10Devico AL,Fouts TR,Shata MT,et al.Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1 .Vaccine,2002,20(15): 1968-1974.?A

共引文献3

同被引文献17

  • 1Lu L. The changing face of HIV in China [ J ]. Nature,2008, (455) :609 -611.
  • 2Pantaleo G,Fauci AS. New concepts in the immunopathogenesis of HIV infection[J]. Annu Rev Immunol, 1995,13:487 -512.
  • 3Shang H, Hart X, Shi X, et al. Genetic and neutralization sensitivity of di- verse HIV-1 env clones from chronically infected patients in China[J]. The Jomnal of Biogical Chemistry,2011,286(16) :14531 - 14541.
  • 4Kirschner M, Monrose V, Paluch M, et al. The production of cleaved, tri- meric human immunodefieiency virus type 1 ( HIV-1 ) envelope glyeo- protein vaccine antigens and infectious pseudoviruses using linear poly- ethylenimine as a transfection reagent[ J]. Protein Expr Purif,2006,48 (1) :61 -68.
  • 5Rollman E, Hinkula 3, Arteaga J, et al. Multi-subtype gpl60 DNA im- munization iduees broadly neutralizing anti-HIV antibodies [ J ]. GeneTher,2004,11 ( 14 ) : 1146 - 1154.
  • 6Gray ES, Madiga MC, Hexanus T, et al. The neutralization breadth of HIV-ldevelops incrementally over four years and is associated with CD4 + T cell decline and high viral load during acute infection[ J]. J Virol,2011,85 (10) :4828 -4840.
  • 7Verkoczy L, Kelsoe G, Moody MA, et al. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies [ J ].Curr Opin Immuno1,2011,23 ( 3 ) :383 - 390.
  • 8Hu X, Hong K, Zhao C, et al. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B9-infected former plasma donors from China naive to antiretroviral therapy [ J ]. Journal of General Virology,2012,93 (Ptl0) :2267 - 2278.
  • 9王倩,尚红,张子宁,等.中国HIV-1感染人群中和抗体水平与疾病进展关系研究[C].第五次全国中青年检验医学学术会议论文汇编,2006:3.
  • 10李育芬,申峰.与HIV感染及艾滋病进程相关因素的研究进展[J].中国公共卫生管理,2008,24(2):151-153. 被引量:9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部